IMHO GT Biopharma soon will turn into a leading player in the biotechnology industry. I expect this 2018 to be a similarly productive year as compared to 2017 but with more of an emphasis on creating shareholder value by hitting our clinical and pre-clinical milestones vs reducing debt and recruiting management. I' pretty sure $GTBP will be listed on NASDAQ and will appoint additional experienced employees and board members.
News 
Market Data 
Discover 
